UniPR129

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 563137

CAS#: 1639159-47-9

Description: UniPR129 is a competitive Eph-ephrin antagonist that acts by blocking in vitro angiogenesis at low micromolar concentrations.


Chemical Structure

img
UniPR129
CAS# 1639159-47-9

Theoretical Analysis

MedKoo Cat#: 563137
Name: UniPR129
CAS#: 1639159-47-9
Chemical Formula: C36H52N2O4
Exact Mass: 576.39
Molecular Weight: 576.820
Elemental Analysis: C, 74.96; H, 9.09; N, 4.86; O, 11.09

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: UniPR129; Uni-PR-129; Uni PR 129;

IUPAC/Chemical Name: (S)-3-((R)-4-((3R,5R,8R,9S,10S,13R,14S,17R)-3-hydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamido)-4-(1H-indol-3-yl)butanoic acid

InChi Key: JGYYGEYIQBZUCC-ZOOAIUBFSA-N

InChi Code: InChI=1S/C36H52N2O4/c1-22(8-13-33(40)38-25(20-34(41)42)18-23-21-37-32-7-5-4-6-27(23)32)29-11-12-30-28-10-9-24-19-26(39)14-16-35(24,2)31(28)15-17-36(29,30)3/h4-7,21-22,24-26,28-31,37,39H,8-20H2,1-3H3,(H,38,40)(H,41,42)/t22-,24-,25+,26-,28+,29-,30+,31+,35+,36-/m1/s1

SMILES Code: OC(C[C@H](CC1=CNC2=C1C=CC=C2)NC(CC[C@@H](C)[C@H]3CC[C@H]4[C@@H]5CC[C@@H]6C[C@H](O)CC[C@]6(C)[C@H]5CC[C@@]43C)=O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 576.82 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Giorgio C, Incerti M, Corrado M, Rusnati M, Chiodelli P, Russo S, Callegari D, Ferlenghi F, Ballabeni V, Barocelli E, Lodola A, Tognolini M. Pharmacological evaluation of new bioavailable small molecules targeting Eph/ephrin interaction. Biochem Pharmacol. 2018 Jan;147:21-29. doi: 10.1016/j.bcp.2017.11.002. Epub 2017 Nov 10. PubMed PMID: 29129483.

2: Incerti M, Russo S, Callegari D, Pala D, Giorgio C, Zanotti I, Barocelli E, Vicini P, Vacondio F, Rivara S, Castelli R, Tognolini M, Lodola A. Metadynamics for Perspective Drug Design: Computationally Driven Synthesis of New Protein-Protein Interaction Inhibitors Targeting the EphA2 Receptor. J Med Chem. 2017 Jan 26;60(2):787-796. doi: 10.1021/acs.jmedchem.6b01642. Epub 2017 Jan 5. PubMed PMID: 28005388.

3: Giorgio C, Russo S, Incerti M, Bugatti A, Vacondio F, Barocelli E, Mor M, Pala D, Hassan-Mohamed I, Gioiello A, Rusnati M, Lodola A, Tognolini M. Biochemical characterization of EphA2 antagonists with improved physico-chemical properties by cell-based assays and surface plasmon resonance analysis. Biochem Pharmacol. 2016 Jan 1;99:18-30. doi: 10.1016/j.bcp.2015.10.006. Epub 2015 Oct 14. PubMed PMID: 26462575.

4: Callegari D, Pala D, Scalvini L, Tognolini M, Incerti M, Rivara S, Mor M, Lodola A. Comparative Analysis of Virtual Screening Approaches in the Search for Novel EphA2 Receptor Antagonists. Molecules. 2015 Sep 17;20(9):17132-51. doi: 10.3390/molecules200917132. PubMed PMID: 26393553.

5: Tognolini M, Incerti M, Lodola A. Are we using the right pharmacological tools to target EphA4? ACS Chem Neurosci. 2014 Dec 17;5(12):1146-7. doi: 10.1021/cn500285h. Epub 2014 Nov 18. Review. PubMed PMID: 25405504.

6: Hatziapostolou M, Polytarchou C. EPH receptor/ephrin system: in the quest for novel anti-angiogenic therapies: Commentary on Hassan-Mohamed et al., Br J Pharmacol 171: 5195-5208. Br J Pharmacol. 2015 Sep;172(18):4597-4599. doi: 10.1111/bph.12718. PubMed PMID: 24724581; PubMed Central PMCID: PMC4562520.

7: Hassan-Mohamed I, Giorgio C, Incerti M, Russo S, Pala D, Pasquale EB, Zanotti I, Vicini P, Barocelli E, Rivara S, Mor M, Lodola A, Tognolini M. UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations. Br J Pharmacol. 2014 Dec;171(23):5195-208. doi: 10.1111/bph.12669. Epub 2014 Aug 28. PubMed PMID: 24597515; PubMed Central PMCID: PMC4294034.